Reply
Open Access
- 15 December 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (12) , 2101-2102
- https://doi.org/10.1086/324362
Abstract
Sir—We read with interest the letter from Dr. Williams [1] regarding our article on ototoxicity associated with the use of nucleoside analog reverse-transcriptaKeywords
This publication has 8 references indexed in Scilit:
- Ototoxicity may be associated with protease inhibitor therapy.Clinical Infectious Diseases, 2001
- Ototoxicity Associated with Use of Nucleoside Analog Reverse Transcriptase Inhibitors: A Report of 3 Possible Cases and Review of the LiteratureClinical Infectious Diseases, 2001
- A Study of the Pharmacokinetics of Azithromycin and Nelfinavir When Coadministered in Healthy VolunteersThe Journal of Clinical Pharmacology, 2000
- HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833Biochemical Pharmacology, 1999
- Relationship of Adverse Events to Serum Drug Levels in Patients Receiving High-Dose Azithromycin for Mycobacterial Lung DiseaseClinical Infectious Diseases, 1997
- Azithromycin-Related Ototoxicity in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1997
- Ototoxicity with azithromycinThe Lancet, 1994
- Otologic And Neurotologic Manifestations Of Acquired Immunodeficiency SyndromeOtolaryngologic Clinics of North America, 1992